HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough head and neck cancers enters Late-Stage testing
Disease control OngoingThis study is testing if adding a new drug called INBRX-106 to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that has spread or returned. It will involve about 410 patients whose cancer expresses a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New combo attack on tough head and neck cancer recurrences
Disease control OngoingThis study is for people whose head and neck cancer has come back or who have a new, related cancer in the same area. It is testing whether adding an immunotherapy drug (pembrolizumab/Keytruda) to a short, precise course of radiation is better at keeping the cancer from growing a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New cancer drug AB598 enters first human trials
Disease control OngoingThis is the first human study testing the safety of an experimental drug called AB598 in people with advanced cancers. The trial will enroll 40 participants with various cancers including lung, stomach, bladder, and breast cancer to determine safe dosage levels and monitor side e…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Four-Drug attack on tough head and neck cancers
Disease control OngoingThis study is testing a combination of four different drugs for adults with advanced head and neck cancer that has returned or spread after prior treatment. The goal is to see if this multi-pronged approach can shrink tumors. The drugs work together by helping the immune system f…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New antibody drug trial offers hope for Tough-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new antibody drug called GEN1042 to see if it's safe and can help control advanced solid tumors. Researchers are giving GEN1042 alone or combined with another cancer drug (pembrolizumab) to about 350 adults with cancers like lung, colorectal, m…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists hunt for clues to make cancer immunotherapy work for more patients
Knowledge-focused OngoingThis study aims to find better ways to predict which patients with advanced head and neck cancer will benefit from the immunotherapy drug nivolumab. Researchers will analyze blood and tumor samples from 50 patients to look for biological markers linked to treatment success. The g…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC